Variables* | Value, Mean (SD)/n (%) | Survival Analysis | |||
---|---|---|---|---|---|
Bivariate | Multivariate CI) | ||||
HR (95% CI) | p | HR (95% | p | ||
Total n | 172 | — | — | — | — |
Age at baseline, yrs | 53 ± 13 | 1.02 (0.99, 1.05) | 0.3104 | 1.03 (1.00, 1.06) | 0.0389 |
Female sex | 130/172 (75.6) | 1.40 (0.65, 3.04) | 0.3898 | — | — |
BMI, kg/m2 | 25.4 ± 4.8 | 0.98 (0.91, 1.06) | 0.6655 | — | — |
Smoking status | 1.50 (0.78, 2.86) | 0.2208 | — | — | |
Ever | 52 (30) | ||||
Never | 117 (69) | ||||
Serology | |||||
Anticentromere antibody | 10/70 (14) | 0.77 (0.27,2.23)‡ (either positive) | 0.6302 (either positive) | — | — |
Scl-70 antibody | 66/136 (49) | 0.74 (0.35, 1.58) | 0.436 | — | — |
Limited (vs diffuse) SSc | 65 (38) | 0.78 (0.42, 1.45) | 0.4316 | — | — |
Pulmonary function | |||||
FVC % predicted | 78.0 ± 21 | 0.96 (0.95, 0.98) | < 0.0001 | 0.97 (0.95, 0.99) | 0.0009 |
DLCO % predicted | 59.9 ± 17.7 | 0.96 (0.95, 0.98) | < 0.0001 | 0.97 (0.96, 0.99) | 0.0004 |
6-min walk, m | 410 ± 121 | 0.997 (0.989, 1.005) | 0.4397 | — | — |
Pulmonary hypertension† | 50 (30) | 3.84 (1.15, 12.83) | 0.0188 | — | — |
Immune suppressive treatment at baseline | 45 (24) | 2.45 (1.16, 5.18) | 0.0160 | — | — |
↵* Variables at time of initial observation.
↵† Echocardiography showing right ventricular systolic pressure > 35 mmHg and/or right ventricular dilatation or dysfunction.
↵‡ Effect of serology on survival studied according to the presence of either anti-Scl-70 or anticentromere antibody-positive. BMI: body mass index; FVC: forced vital capacity; SSc: systemic sclerosis.